馆长 发表于 2025-3-23 13:02:51

http://reply.papertrans.cn/1/84/8344/8344-11.png

ADOPT 发表于 2025-3-23 14:30:13

http://reply.papertrans.cn/1/84/8344/8344-12.png

抵消 发表于 2025-3-23 19:00:17

Submitted on: 29 September 2013.
Revised on: 17 January 2014.
Accepted on: 24 February 2014.

___________________Endocrine Metabolic & Immune Disorders-Drug Targets

不怕任性 发表于 2025-3-24 00:02:55

Submitted on: 16 November 2005.
Revised on: 13 January 2006.
Accepted on: 07 March 2006.

___________________Endocrine Metabolic & Immune Disorders-Drug Targets

Allege 发表于 2025-3-24 03:27:35

http://reply.papertrans.cn/1/84/8344/8344-15.png

labyrinth 发表于 2025-3-24 07:23:46

Submitted on: 21 May 1999.
Revised on: 09 August 1999.
Accepted on: 20 August 1999.

___________________Endocrine Metabolic & Immune Disorders-Drug Targets

disparage 发表于 2025-3-24 13:28:34

Submitted on: 20 December 2004.
Revised on: 11 April 2005.
Accepted on: 17 May 2005.

___________________Endocrine Metabolic & Immune Disorders-Drug Targets

装入胶囊 发表于 2025-3-24 15:42:38

http://reply.papertrans.cn/1/84/8344/8344-18.png

座右铭 发表于 2025-3-24 22:26:46

Submitted on: 02 March 2002.
Revised on: 27 June 2002.
Accepted on: 27 July 2002.

___________________Endocrine Metabolic & Immune Disorders-Drug Targets

prolate 发表于 2025-3-25 02:49:26

Submitted on: 23 January 2010.
Revised on: 04 March 2010.
Accepted on: 24 March 2010.

___________________Endocrine Metabolic & Immune Disorders-Drug Targets
页: 1 [2] 3 4
查看完整版本: SCIE期刊Endocrine Metabolic & Immune Disorders-Drug Targets 2024/2025影响因子:2.108 (ENDOCR METAB IMMUNE) (1871-5303). (IMMUN